Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy in BRAF mutant colorectal cancer, emergence of acquired resistance limits clinical benefit. Here, we undertook a comprehensive effort to define mechanisms underlying drug resistance with the goal of guiding development of therapeutic strategies to overcome this limitation. We generated a broad panel of BRAF mutant resistant cell line models across seven different clinically-relevant drug combinations. Combinatorial drug treatments were able to abrogate ERK1/2 phosphorylation in parental sensitive cells, but not in their resistant counterparts, indicating that resistant cells escaped drug treatments through one or more mechanisms leading to biochemical reactivation of the MAPK signaling pathway. Genotyping of resistant cells identified gene amplification of EGFR, KRAS and mutant BRAF, as well as acquired mutations in KRAS, EGFR, and MAP2K1. These mechanisms were clinically relevant, as we identified emergence of a KRAS G12C mutation and increase of mutant BRAF V600E allele frequency in the circulating tumor DNA of a patient at relapse from combined treatment with BRAF and MEK inhibitors. In order to identify therapeutic combinations capable of overcoming drug resistance, we performed a systematic assessment of candidate therapies across the panel of resistant cell lines. Independent of the molecular alteration acquired upon drug pressure, most resistant cells retained sensitivity to vertical MAPK pathway suppression when combinations of ERK, BRAF, and EGFR inhibitors were applied. These therapeutic combinations represent promising strategies for future clinical trials in BRAF mutant colorectal cancer.

Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer

Oddo D;Barault L;Arena S;Bartolini A;Crisafulli G;Boscaro V;Buscarino M;Cancelliere C;Siravegna G;Gallicchio M;Bardelli A;Di Nicolantonio F.
Last
2016

Abstract

Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy in BRAF mutant colorectal cancer, emergence of acquired resistance limits clinical benefit. Here, we undertook a comprehensive effort to define mechanisms underlying drug resistance with the goal of guiding development of therapeutic strategies to overcome this limitation. We generated a broad panel of BRAF mutant resistant cell line models across seven different clinically-relevant drug combinations. Combinatorial drug treatments were able to abrogate ERK1/2 phosphorylation in parental sensitive cells, but not in their resistant counterparts, indicating that resistant cells escaped drug treatments through one or more mechanisms leading to biochemical reactivation of the MAPK signaling pathway. Genotyping of resistant cells identified gene amplification of EGFR, KRAS and mutant BRAF, as well as acquired mutations in KRAS, EGFR, and MAP2K1. These mechanisms were clinically relevant, as we identified emergence of a KRAS G12C mutation and increase of mutant BRAF V600E allele frequency in the circulating tumor DNA of a patient at relapse from combined treatment with BRAF and MEK inhibitors. In order to identify therapeutic combinations capable of overcoming drug resistance, we performed a systematic assessment of candidate therapies across the panel of resistant cell lines. Independent of the molecular alteration acquired upon drug pressure, most resistant cells retained sensitivity to vertical MAPK pathway suppression when combinations of ERK, BRAF, and EGFR inhibitors were applied. These therapeutic combinations represent promising strategies for future clinical trials in BRAF mutant colorectal cancer.
76
15
4504
4515
http://cancerres.aacrjournals.org/content/76/15/4504.long
BRAF, colorectal cancer, drug resistance, cetuximab, ERK inhibitors
Oddo, D; Sennott, Em; Barault, L; Valtorta, E; Arena, S; Cassingena, A; Filiciotto, G; Marzolla, G; Elez, E; van Geel RM, ; Bartolini, A; Crisafulli, G; Boscaro, V; Godfrey, Jt; Buscarino, M; Cancelliere, C; Linnebacher, M; Corti, G; Truini, M; Siravegna, G; Grasselli, J; Gallicchio, M; Bernards, R; Schellens, Jh; Tabernero, J; Engelman, Ja; Sartore-Bianchi, A; Bardelli, A; Siena, S; Corcoran, Rb; Di Nicolantonio, F.
File in questo prodotto:
File Dimensione Formato  
Oddo_BRAF_CancerRes_postprint_2016.pdf

Accesso aperto con embargo fino al 17/06/2017

Descrizione: Oddo_BRAF_CancerRes_postprint_2016
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 2.76 MB
Formato Adobe PDF
2.76 MB Adobe PDF Visualizza/Apri
Oddo_CancerRes_2016_PublisherPDF_Suppl.pdf

Accesso riservato

Descrizione: Articolo principale (PDF Editoriale) e dati supplementari
Tipo di file: PDF EDITORIALE
Dimensione 2.08 MB
Formato Adobe PDF
2.08 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Oddo Cancer Res 2016 76 4504.full.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 1.41 MB
Formato Adobe PDF
1.41 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1569569
Citazioni
  • ???jsp.display-item.citation.pmc??? 44
  • Scopus 72
  • ???jsp.display-item.citation.isi??? 71
social impact